The blood test can be used along with other diagnostic tools to evaluate the likelihood of a patient having amyloid pathology consistent with AD. Credit: OsloMetX from Pixabay.

Quanterix has introduced the new biomarker blood test, LucentAD, to facilitate the diagnosis of Alzheimer’s disease (AD) in patients.

The test has been designed to help assess patients experiencing cognitive symptoms consistent with the early signs of AD.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Healthcare providers can use this test along with other diagnostic tools to rapidly evaluate the likelihood of a patient having amyloid pathology consistent with the disease.

Designed to be run by the company’s clinical laboratory improvement amendments (CLIA), the test measures phosphorylated tau protein isoform in plasma.

The isoform is phosphorylated at the 181 residue of the protein (p-Tau 181), a low-abundance protein in blood that needs high analytical sensitivity for its reliable measurement.

Its concentration in plasma and cerebrospinal fluid has been positively correlated to amyloid pathology present in the brain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

LucentAD leverages the Simoa p-Tau 181 assay, which was assessed in large longitudinal and cross-sectional cohorts.

Quanterix CEO Masoud Toloue said: “A year ago, Quanterix announced the validation of our laboratory-developed test to quantitatively measure p-Tau 181 in plasma as an aid in diagnostic evaluation of AD.

“The launch of Lucent Diagnostics and availability of the LucentAD test expands access to our p-Tau 181 test for healthcare providers and marks an important step in our goal to help build a global AD testing infrastructure.”

The introduction of the LucentAD test coincides with the FDA approval of Eisai’s Leqembi for AD.

In the Leqembi labelling for accelerated approval, various biomarkers including plasma p-Tau 181, which was measured using Quanterix’s Simoa platform, were employed to track response to therapy.